CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma's earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia. It also evaluates its pipeline candidate paclitaxel poliglumex, which targets solid tumors.

TypePublic
HQSeattle, US
Founded1992
Size (employees)100 (est)
Websitectibiopharma.com
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at CTI BioPharma

Adam R. Craig

Adam R. Craig

President and Chief Executive Officer
Bruce J. Seeley

Bruce J. Seeley

EVP, Chief Operating Officer
David H. Kirske

David H. Kirske

EVP, Chief Financial Officer
Show more

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave
Show all (1)
Report incorrect company information

CTI BioPharma Financials and Metrics

CTI BioPharma Revenue

CTI BioPharma's revenue was reported to be $25.15 m in FY, 2017
USD

Revenue (Q3, 2018)

723.0k

Net income (Q3, 2018)

(14.8m)

EBIT (Q3, 2018)

(14.8m)

Market capitalization (22-Jan-2019)

65.5m

Closing stock price (22-Jan-2019)

1.1

Cash (30-Sep-2018)

52.9m

EV

16.5m
CTI BioPharma's current market capitalization is $65.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

34.7m60.1m16.1m57.4m25.1m

Revenue growth, %

73%(73%)256%

Cost of goods sold

895.0k

Gross profit

59.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

362.0k1.4m1.3m39.5m2.7m1.1m964.0k36.5m7.4m4.4m754.0k22.2m1.7m10.5m613.0k723.0k

General and administrative expense

8.5m16.8m13.8m12.6m12.3m12.6m13.7m11.3m9.6m15.2m10.7m8.0m5.8m5.4m4.9m5.6m

R&D expense

7.2m12.2m14.0m16.5m17.5m19.3m18.4m20.8m16.7m17.7m9.3m8.9m7.6m9.7m9.1m9.7m

Operating expense total

15.9m29.1m28.0m32.1m30.2m32.1m32.9m32.3m26.4m33.1m20.1m17.0m13.5m15.1m29.1m15.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6m70.9m128.2m44.0m27.2m

Accounts Receivable

235.0k2.0m282.0k378.0k4.0k

Inventories

5.1m3.4m2.8m1.5m550.0k

Current Assets

80.5m80.5m135.0m55.8m46.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

27.2m50.6m33.2m29.9m44.4m54.9m46.4m104.6m76.7m61.6m33.3m74.7m52.8m104.6m65.4m52.9m

Accounts Receivable

540.0k503.0k613.0k1.2m1.3m880.0k422.0k666.0k559.0k620.0k311.0k480.0k180.0k

Inventories

3.7m5.0m5.0m4.5m3.6m3.6m2.6m2.9m2.6m2.6m1.5m1.5m601.0k564.0k

Current Assets

33.7m59.9m42.3m55.9m53.5m63.9m53.3m113.9m88.9m67.9m36.8m78.4m57.5m107.8m95.1m82.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.5m)(94.2m)(120.8m)(53.0m)

Depreciation and Amortization

1.6m1.1m990.0k831.0k717.0k

Inventories

(3.3m)46.0k(402.0k)567.0k1.1m

Accounts Payable

(5.8m)1.5m4.4m(3.0m)(4.7m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(29.2m)(56.7m)(52.3m)(28.6m)(61.7m)(94.7m)3.0m(17.0m)(46.4m)(19.8m)

Depreciation and Amortization

360.0k616.0k875.0k512.0k757.0k232.0k442.0k636.0k193.0k382.0k541.0k152.0k302.0k448.0k

Inventories

50.0k22.0k115.0k3.6m245.0k510.0k68.0k269.0k339.0k48.0k140.0k1.0m

Accounts Payable

(410.0k)1.3m1.4m10.3m5.0m7.1m7.1m3.7m3.3m4.6m(3.3m)(5.3m)(419.0k)1.1m(493.0k)
USDY, 2018

EV/EBIT

-1.1 x

EV/CFO

-0.6 x

Debt/Equity

0.1 x

Financial Leverage

1.7 x
Show all financial metrics

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials Products

2
Show all operating metrics
Report incorrect company information

CTI BioPharma News and Updates

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

SEATTLE, Dec. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a...

CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development

SEATTLE, Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients...

CTI BioPharma Announces Restructuring Plan

SEATTLE, Dec. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of the...

CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018

SEATTLE, Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets. Following the announcement,...

CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

SEATTLE, Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel. Presentation details: Event:...
Report incorrect company information

CTI BioPharma Company Life and Culture

Report incorrect company information

CTI BioPharma Frequently Asked Questions

  • When was CTI BioPharma founded?

    CTI BioPharma was founded in 1992.

  • Who are CTI BioPharma key executives?

    CTI BioPharma's key executives are Adam R. Craig, Bruce J. Seeley and David H. Kirske.

  • How many employees does CTI BioPharma have?

    CTI BioPharma has 100 employees.

  • What is CTI BioPharma revenue?

    Latest CTI BioPharma annual revenue is $25.1 m.

  • What is CTI BioPharma revenue per employee?

    Latest CTI BioPharma revenue per employee is $251.5 k.

  • Who are CTI BioPharma competitors?

    Competitors of CTI BioPharma include Cardiorentis, Retrophin and Palatin Technologies.

  • Where is CTI BioPharma headquarters?

    CTI BioPharma headquarters is located at 600 3101 Western Ave, Seattle.

  • Where are CTI BioPharma offices?

    CTI BioPharma has an office in Seattle.

  • How many offices does CTI BioPharma have?

    CTI BioPharma has 1 office.